Johnson & Johnson's earnings call highlighted a return to sales growth in a challenging environment, driven by strong performance in some segments, particularly pharmaceuticals (immunology, HIV treatments).  However, the call also included concerns about pricing pressures, especially in the Medical Devices & Diagnostics and Consumer segments, and the impact of the McNeil recalls, which will likely cause short-term stock price fluctuations.

[1]
